Although the signaling events that induce different forms of programmed cell death are well defined, the subsequent immune responses to dying cells in the context of cancer remain relatively unexplored. Necroptosis occurs downstream of the receptor-interacting protein kinases RIPK1 and RIPK3, whose activation leads to lytic cell death accompanied by de novo production of proinflammatory mediators. Here, we show that ectopic introduction of necroptotic cells to the tumor microenvironment promotes BATF3 + cDC1− and CD8 + leukocyte-dependent antitumor immunity accompanied by increased tumor antigen loading by tumor-associated antigen-presenting cells. Furthermore, we report the development of constitutively active forms of the necroptosis-inducing enzyme RIPK3 and show that delivery of a gene encoding this enzyme to tumor cells using adeno-associated viruses induces tumor cell necroptosis, which synergizes with immune checkpoint blockade to promote durable tumor clearance. These findings support a role for RIPK1/RIPK3 activation as a beneficial proximal target in the initiation of tumor immunity. Considering that successful tumor immunotherapy regimens will require the rational application of multiple treatment modalities, we propose that maximizing the immunogenicity of dying cells within the tumor microenvironment through specific activation of the necroptotic pathway represents a beneficial treatment approach that may warrant further clinical development.
INTRODUCTION
Tumor immunotherapy, which boosts the ability of the body's own immune system to recognize and kill transformed cells, constitutes an immensely promising advance in the modern treatment of cancer. The efficacy of existing T cell-targeted therapies such as immune checkpoint blockade (ICB) can often be boosted upon coadministration of cytotoxic treatments such as irradiation (1, 2) . However, the specific forms of programmed cell death (PCD) initiated upon administration of cytotoxic therapies to tumor cells are often not rigorously defined (3) . Considering the growing body of evidence supporting differential immune activation or suppression in response to distinct PCD modalities (4) , strategies to maximize the immunogenicity of dying tumor cells could potentially function to boost the effects of coadministered treatments including ICB.
Cells can undergo distinct forms of PCD in response to cellular stress, pathogen infection, and organismal development (5, 6) . Apoptosis occurs after activation of a family of proteases termed caspases, and the clearance of apoptotic debris is often associated with tolerogenic signaling (7) . These immunomodulatory processes include the caspase-directed inactivation of immunostimulatory damage-associated molecular patterns (DAMPs) such as high-mobility group box 1 protein (8) , as well as immunosuppressive functions of the Tyro3/Axl/Mertk receptor tyrosine kinases in promoting tissue repair phenotypes in phagocytes that have engulfed apoptotic debris (9) . Apoptosis is believed to be the mechanism of PCD in tumor cells after administration of a wide variety of anticancer drugs, including chemotherapeutic agents (10, 11) and specific inducers of apoptosis (12) (13) (14) . Induction of immune tolerance by apoptotic cells may therefore limit synergistic effects when combining these anticancer compounds with ICB or other immunotherapy regimens.
Necroptosis is a form of PCD that occurs downstream of the receptor-interacting protein kinases RIPK1 and RIPK3, which assemble into an oligomeric complex termed the "necrosome" (15, 16) . A growing body of evidence supports the idea that necroptosis is a more potently immunogenic form of PCD than apoptosis in certain contexts (4) . Necroptotic cells undergo rapid membrane permeabilization via the executioner protein mixed-lineage kinase-like (MLKL), leading to the release of intracellular contents including immunogenic DAMPs that can activate innate immune pattern recognition receptors (PRRs) (17) (18) (19) . Furthermore, death-independent functions of RIPK3 have also been recently defined, including inflammatory chemokine and cytokine production that can promote cross-priming of CD8 + T cell vaccination responses (20) and confer protection during viral infection (21) . Therefore, a model emerges in which necroptosis can function as an alternative PCD modality that can eliminate caspase-compromised cells in the event of infection while simultaneously releasing a payload of inflammatory signals to recruit and activate immune cells (22) . These findings have not yet been comprehensively applied to the field of tumor immunology, in part due to technical limitations related to the manipulation of PCD programs in vivo. Specific targeting of necroptosis using endogenous signaling components is difficult, because there is extensive regulatory cross-talk between extrinsic apoptotic and necroptotic signaling pathways (16) . This is further complicated by the fact that many tumors have mutated or silenced either caspases (23) or the RIPKs (24) . Given these obstacles, the specific differential effects of enforced RIPK3 activation versus caspase-8 or caspase-9 activation within the tumor microenvironment (TME) have not been described.
Here, we describe a beneficial role for activation of the necroptotic pathway components RIPK1 and RIPK3 within the TME. Using engineered versions of pro-death enzymes, we present a reductionist system that circumvents endogenous pro-death signaling pathways within tumor cells. Ectopic activation of RIPK3 promotes tumor antigen loading by tumor antigen-presenting cells (APCs) associated with enhanced CD8
+ leukocyte-mediated antitumor responses, which leads to systemic tumor control that synergizes robustly with ICB coadministration. These beneficial effects occur specifically after administration of necroptotic cells within solid tumors but not after exposure to apoptotic cells or cells dying via lytic necrosis, indicating that these protective effects are due to signals specifically derived from the RIPK1/RIPK3 necrosome complex. We also present a tractable system for the induction of necroptosis in tumor cells in situ using engineered adeno-associated viruses (AAVs), which successfully recapitulate tumor control effects after necroptosis initiation. Collectively, these findings demonstrate that RIPK1/RIPK3 activation in established solid tumors promotes robust antitumor immunity.
RESULTS

Necroptotic cells confer tumor control across multiple syngeneic flank tumor models
To assess the impact of necroptotic tumor cell death on gross tumor outgrowth responses, we used a model of intratumoral dying cell administration that allowed us to precisely control the timing and number of cells undergoing various cell death pathways within the TME. We used constructs encoding chimeric versions of pro-death proteins fused to activatable ("ac") FKBP F36V domains, which we have previously shown allow activation of the chimeric protein after incubation with a synthetic bivalent homolog of rapamycin that functions as a nontoxic ligand (25) . Tumor cells transduced with activatable versions of either proapoptotic caspase-8 (acCASP8), proapoptotic caspase-9 (acCASP9), or pronecroptotic RIPK3 (acRIPK3) (Fig. 1A) were pulsed with ligand drug in vitro to enforce oligomerization of these pro-death enzymes and then injected intratumorally into pre-established syngeneic flank tumors. In this system, ectopically administered cells are alive at the time of injection but are fated to undergo respective forms of PCD within the TME, accompanied by any signaling activity induced downstream of acCASP8, acCASP9, or acRIPK3. Transduction with proapoptotic acCASP9 was better tolerated in tumor cell lines, whereas acCASP8 was better tolerated in fibroblast cell lines. Using this model, we observed that administration of autologous necroptotic (acRIPK3), but not apoptotic (acCASP9), tumor cells into cell type-matched tumors conferred control of tumor outgrowth and extended survival of animals bearing either B16.F10-ovalbumin (OVA) melanoma flank tumors (Fig. 1B and fig. S1B ) or Lewis lung (LL/2)-OVA adenocarcinoma flank tumors (Fig. 1C and fig. S1C ).
Unexpectedly, the tumor control effects of necroptosis did not require that necroptotic cells themselves carry tumor antigens, because injection of an unrelated fibroblast line, NIH 3T3, similarly led to tumor control and extension of animal survival after necroptotic, but not apoptotic (acCASP8) fibroblast administration in B16.F10-OVA ( Fig. 1D and fig. S1D ), LL/2-OVA ( Fig. 1E and fig. S1E) , and E.G7-OVA thymoma ( Fig. 1F and fig. S1F ) flank tumors (26) . These tumor control effects were not an artifact of the immunodominant OVA epitope expressed by tumor cells, because administration of necroptotic fibroblasts also conferred tumor outgrowth and survival extension in mice implanted with non-OVA-expressing B16.F10 (Fig. 1G and  fig. S1G ) or LL/2 ( Fig. 1H and fig. S1H ) flank tumors. These data indicate that necroptotic cells delay tumor outgrowth and even confer complete tumor clearance in a small percentage of animals across multiple syngeneic flank tumor models.
Considering these findings, we next tested whether this treatment could act systemically in a bilateral flank tumor model, where a single mouse is implanted with separate B16.F10-OVA tumors on either flank. After injection of necroptotic fibroblasts into a treated (ipsilateral) tumor, we observed control of flank tumor outgrowth in both the ipsilateral and the untreated (contralateral) tumors (Fig. 1I) , leading to an extension of animal survival (Fig. 1I) . Control of both tumors in this bilateral tumor model indicates an abscopal effect, whereby application of a therapeutic agent to a primary tumor can lead to the control and even elimination of distal, untreated metastases. This effect required tumor antigen matching between the ipsilateral and contralateral tumors, because mice implanted with a B16. F10-OVA ipsilateral tumor and an antigenically disparate LL/2 contralateral tumor failed to exhibit abscopal tumor control after administration of necroptotic fibroblasts ( fig. S1I ). These data suggest that the introduction of necroptotic cells to the TME initiates a systemic immune response to tumor-derived antigens, irrespective of antigen matching between necroptotic cells and the tumor cells themselves.
Tumor control by necroptotic cells requires BATF3
+ cDC1 and CD8 + leukocytes Given the unexpected finding that introduction of necroptotic cells to the TME promoted systemic tumor control irrespective of antigen matching, we sought to establish that the control we observed was immune mediated. BATF3 is a transcription factor required for the development of conventional dendritic cells 1 (cDC1), which are critical for cross-presentation of exogenous antigens to stimulate CD8-mediated immunity and are required for endogenous antitumor immune responses (27) . We found that the tumor control effects of necroptotic fibroblasts required BATF3 + cDC1, because Batf3 −/− mice failed to restrict B16.F10-OVA ( Fig. 2A) or LL/2-OVA ( fig. S2A ) tumor growth compared with controls. Consistent with the critical role for cDC1 in mediating antitumor immunity, we also observed that depletion of CD8 + leukocytes (including both CD8 + cytotoxic T cells and CD8 + DCs) completely abrogated the therapeutic effect of necroptotic fibroblast administration, whereas depletion of CD4 + leukocytes did not affect tumor control responses (Fig. 2B) ; depletion of each leukocyte population was confirmed via flow cytometry ( fig. S2B ). These data indicate that control of tumors after introduction of necroptotic cells is immune mediated and proceeds via activation of CD8 + leukocytes.
Immune-mediated tumor control by necroptotic cells requires NF-B activation within dying cells but not DAMP release
We next investigated the signals emanating from necroptotic cells within the TME that promoted immune activation and tumor control. Because necroptosis is a lytic form of cell death, necroptotic cells might initiate immune responses through the release of DAMP molecules within the TME. To assess this possibility, we first tested the ability of necroptotic fibroblasts to recapitulate tumor control effects in several knockout mouse strains, whose tumor-infiltrating ) all retained the ability to control tumor outgrowth after administration of necroptotic fibroblasts into either B16.F10-OVA (Fig. 3A) or LL/2-OVA ( fig. S3A ) tumors, indicating that the therapeutic effects of necroptotic cells are not strictly mediated through the singular activity of these innate immune signaling components within tumor-infiltrating leukocytes. Furthermore, antibody-mediated blockade of the necrotic cell sensor CLEC9A (28) did not affect tumor restriction or animal survival extension by necroptotic fibroblasts (Fig. 3B) ; effective blockade of . n = 9 to 11 mice per group. **P < 0.01, ***P < 0.001, and ****P < 0.0001. Black arrows indicate intratumoral dying cell injections. Error bars represent SEM. Data are pooled from three to five independent experiments.
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CLEC9A expression was confirmed on dendritic cell (DC) subsets in both the spleen and tumor ( fig. S3B ). Together, these results indicate that tumor control by necroptotic cells is not mediated solely through the activation of any of these individual innate immune signaling pathways.
Our previous findings indicate that RIPK3 activation induces nuclear factor B (NF-B)-mediated transcriptional responses in addition to lytic cell death (20) . We therefore sought to separate these two potentially immunostimulatory processes to understand the contribution of each to necroptosis-mediated tumor control. To do this, we first administered fibroblasts dying via either necroptosis or lytic necrosis into established B16.F10-OVA tumors, using three different forms of lytic necrotic fibroblasts ( fig. S1A ): (i) cells expressing a mutated version of activatable RIPK3 lacking the RIP homotypic interaction motif (RHIM) domain (acRIPK3C), which cannot recruit and activate RIPK1 to induce downstream NF-B-mediated inflammatory gene transcription yet maintains the ability to activate MLKL to induce pore formation and lytic cell death (20) ; (ii) cells expressing an activatable version of MLKL (acMLKL) to induce pore formation and lytic cell death in the absence of upstream RIPK3 activation (29) ; and (iii) cells that were mechanically lysed via repeated freeze-thaw cycles immediately before injection. All three forms of lytic necrotic cells similarly release cell-associated DAMPs due to loss of plasma membrane integrity but lack activation of the RIPK1/NF-B signaling axis that is otherwise observed upon activation of full-length RIPK3 in necroptotic NIH 3T3 cells (20) .
We observed that all three treatments of lytic necrotic fibroblasts failed to confer tumor control and extend animal survival compared to fibroblasts dying via acRIPK3-mediated necroptosis, both in single B16.F10-OVA tumors (Fig. 3C ) and using acRIPK3C fibroblasts in single LL/2-OVA ( fig. S3C, left panels) or E.G7-OVA tumors ( fig. S3C , right panels). Consistent with this, administration of acRIPKC fibroblasts failed to confer tumor control (Fig. 3D) and extension of survival ( fig. S3D ) in bilateral B16.F10-OVA tumorbearing mice. These results revealed that DAMP release is not sufficient for the tumor control effects of necroptotic fibroblasts within the TME, suggesting instead that signaling activities downstream of RIPK1/RIPK3 necrosome complex formation and activation may play a role.
To more directly test whether the immunogenicity of necroptotic fibroblasts in our tumor model depended on intact NF-B activation in the dying cells, we preincubated NIH 3T3 cells +acRIPK3 with an irreversible inhibitor of nuclear factor B (NFB) signaling, BAY-117085, before pulsing with activator drug and injection + or CD8 + leukocytes. n = 6 to 11 mice per group. *P < 0.05, **P < 0. (Fig. 3F , left panel) and survival extension (Fig. 3F, right panel) responses necroptotic fibroblasts. n = 7 to 9 mice per group. (G) Assessment of systemic inflammation via Luminex assay for inflammatory serum cytokines and chemokines 48 hours after intratumoral dying NIH 3T3 injection. DMXAA-injected mice were included as a positive control for systemic inflammatory cytokine production. The gray dashed line represents the limit of detection. n = 3 to 5 mice per group. (H) B16.F10-OVA tumor growth curves after intratumoral (IT), intraperitoneal (IP), distal subcutaneous (distal subQ), or intravenous (IV) injection of necroptotic fibroblasts. n = 7 to 9 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Black arrows indicate intratumoral dying cell injections. Error bars represent SEM. Data are pooled from two to five independent experiments. ns, not significant.
as seen in mice that received MLKL-sufficient necroptotic fibroblasts. Together, these results indicate that transcriptional signaling downstream of RIPK1/RIPK3/NF-B activation is responsible for the immunogenicity of necroptotic fibroblasts in the TME and that this occurs independently of DAMP release by dying cells.
Our data point to the production of NF-kB-dependent cytokines as key to tumor control by necroptotic cells. Because these cytokines can act both locally and systemically, we next tested whether the introduction of necroptotic cells to the TME might drive systemic inflammatory or immune responses. To do this, we measured levels of inflammatory mediators in sera harvested from B16.F10-OVA tumor-bearing mice after necroptotic cell administration. There were no differences between treatment groups with respect to systemic levels of inflammatory chemokines and cytokines relevant for antitumor responses, including interferon- (IFN-), tumor necrosis factor- (TNF-), CCL5, and CXCL10 (Fig. 3G ), or chemokines and cytokines known to be produced by necroptotic NIH 3T3 fibroblasts, including interleukin-6 (IL-6), CXCL1, and CCL2 ( fig. S3G ) (20) . Consistent with this, injection of necroptotic fibroblasts into spatially distinct locations distal from the tumor site, including intraperitoneally, intravenously, or subcutaneously on the opposite flank to the tumor, all failed to confer tumor outgrowth control (Fig. 3H ) or extend animal survival ( fig. S3H ) compared with intratumoral injection of necroptotic fibroblasts. These data indicate that administration of necroptotic fibroblasts does not lead to tumor control through nonspecific systemic inflammation, suggesting that the therapeutic effect of this treatment is due to local mechanisms exerted specifically within the TME.
Necroptosis promotes antitumor CD8
+ T cell responses and synergizes with ICB We next sought to understand the nature of the immune response instigated by introduction of necroptotic cells to the TME. To do this, we first assessed the effects of dying cell administration on cytotoxic CD8
+ T cells, a critical mediator of antitumor immunity. Using flow cytometric analysis to identify subsets of OVA-specific (SIINFEKL-H2K b+ ) CD8 + T cells isolated from B16.F10-OVA tumors ( fig. S4A ), we observed increased numbers of OVA-specific T cells expressing markers of proliferation (Ki67 + ), effector function (GranzymeB), and general activation (CD44 hi ) after necroptotic (acRIPK3), but not apoptotic (acCASP8) or lytic necrotic (acRIPK3C), fibroblast administration (Fig.4A ). OVA-specific CD8 + T cells isolated from necroptotic cell-exposed tumor tissue displayed similarly elevated percentages of both CD44 hi and programmed cell death protein 1 (PD-1) + cells ( fig. S4B , left and middle panels), indicating that necroptosis correlated with an overall more activated surface phenotype of intratumoral CD8 + T cells, although these CD8 + T cells did not express higher levels of PD-1 on a per cell basis compared with cells exposed to apoptotic or lytic necrotic fibroblasts ( fig. S4B , right panel). Furthermore, we observed significant increases in the ratios of both activated (CD44 hi ) or tumor-specific (SIINFEKL-H2k b+ ) CD8
+ T cells to CD25 + Foxp3 + regulatory T cells (T regs ) ( Fig. 4B ) specifically within tumors that received necroptotic fibroblasts, indicating that the profile of tumor-infiltrating T cells was skewed toward more favorable cytotoxic CD8 + T cells, rather than an immunosuppressive profile dominated by T reg . These data indicate that exposure to necroptotic cells within the TME is associated with increased numbers of tumor-specific CD8
+ T cells present in the tumor tissue. To characterize the effects of necroptotic cell administration on lymph node priming, we concurrently examined the abundance and quality of CD8 + T cell responses in the tumor-draining lymph node (tdLN) of these mice ( fig. S4C ). We observed an increased frequency ( Fig. 4C) S4D ). We also observed similar increases in the frequency (Fig. 4D) and number (fig. S4D ) of activated, tumor-specific (defined as CD44
hi SIINFEKL-H2k b+ ) CD8 + T cells in the tdLN of necroptotic cell-treated mice. Therefore, in addition to an expansion of favorable CD8 + T cell phenotypes locally within the TME, necroptotic fibroblast injection also resulted in lymph node priming of tumor-reactive cytotoxic CD8 + T cells. To test whether recruitment of these newly primed CD8 + T cells into the TME was required for necroptotic cells to exert tumor control, we coadministered necroptotic fibroblasts with the sphingosine-1-phosphate receptor modulator fingolimod (FTY-720) to inhibit egress of lymphocytes from the tdLN. Blockade of lymphocyte trafficking did not affect B16.F10-OVA tumor control by necroptotic fibroblasts, because FTY-720-treated animals still exhibited effective control over tumor outgrowth and extension of animal survival compared with vehicle-treated controls (Fig. 4E ). Consistent with a lack of influx of newly primed lymphocytes, enumeration of various tumor-associated lymphocyte populations isolated from B16.F10-OVA tumors 48 hours after dying cell administration revealed similar total numbers of CD19 + B cells, CD4 + T cells, and CD8 + T cells within the TME among tumors that received apoptotic (acCASP8), necroptotic (acRIPK3), or lytic necrotic (acRIPK3C) cell injections ( fig. S4E) .
Inhibition of lymph node egress by primed leukocytes also did not alter abscopal tumor control in bilateral B16.F10-OVA tumors ( Fig. 4F and fig. S4F ), suggesting that untreated contralateral tumor control could be mediated by recirculating leukocytes in the periphery. These results show that rapid recruitment of tumor-reactive lymphocytes from the tdLN is not required for growth restriction of treated or distal, untreated tumors responding to necroptotic fibroblast exposure and further implicate local effects of necroptotic cells within the TME.
The efficacy of ICB is often boosted upon coadministration with cytotoxic therapies, including irradiation (2). Because stimuli from necroptotic cells boosted activation of tumor-specific CD8 + T cells both in tumor and in tdLN, we hypothesized that the presence of necroptotic cells within the TME that would synergize with ICB, specifically -PD-1. To test this, we interleaved injections of necroptotic fibroblasts into B16.F10-OVA flank tumors with administration of -PD-1 and observed that mice exhibited significantly improved survival outcomes (Fig. 4G ) and improved tumor growth restriction ( fig. S4G, left panel) , because 71.4% of mice successfully cleared their tumors ( fig. S4G , right panel) after this coadministration regimen. To determine whether this successful combination therapy conferred protective immune memory, we rechallenged mice ~2 months after they successfully cleared their tumors, injecting identical tumor cells into the same flank that bore the initial B16.F10-OVA tumor (Fig. 4H, left panel) . All mice (100%) were protected from tumor rechallenge ( fig. S4H ) and failed to succumb to tumor outgrowth compared with naïve B6/J controls (Fig. 4H, right panel) . Together, these data indicate that necroptosis in the TME can potently synergize with ICB coadministration to promote durable tumor rejection. Exposure to necroptosis in the TME promotes antigen uptake and activation of tumor-associated APCs Our data indicate that necroptosis potentiates antitumor CD8 + T cell responses even when necroptotic cells do not contain tumor antigen, implicating broad activation of tumor-associated APCs as the key effect of necroptotic cells within the TME. We therefore aimed to define necroptosis-induced changes to tumor-associated myeloid cell populations that could function to initiate adaptive immunity. Using a previously published gating strategy to identify subsets of tumor-associated innate immune cells ( fig. S5C) (Fig. 5A and fig. S5A ). This was promising, given that CD103 + DC1 are often viewed as the most functional tumor APC subset with respect to stimulating CD8 + T cell-mediated antitumor immunity (31) (32) (33) . Consistent with this increase in intratumoral CD103 + DC1, we measured significantly elevated levels of the DC chemoattractants CCL3, CCL4, and CCL5 in tumor homogenates after exposure to necroptotic fibroblasts (Fig. 5B) . Considering that CD103 + DC1 can be recruited to the TME via NK cell-derived chemokines (34), we tested whether depletion of NK cells ( fig. S5B, right panel) abrogated the therapeutic effect of necroptotic fibroblasts. NK cell depletion had no effect on tumor control and survival extension ( fig. S5B, left panel) by necroptotic fibroblasts.
We next evaluated the phenotype of phagocytic tumor APCs with respect to tumor antigen loading and their activation status. To do this, we implanted mice with B16.F10-OVA cells that also express the bright and stable fluorophore zsGreen, then gated on zsGreen + tumor-associated phagocytes to identify tumor APCs that have ingested tumor-derived material (Fig. 5C and fig. S5C ). Using this gating strategy, we identified zsGreen + subsets of six primary tumor APC populations: bulk CD24 + DCs, CD103 + DC1, CD11b + DC2, bulk F4/80 + tumor-associated macrophages (TAM), CD11b + TAM1, and CD11c + TAM2. The proportion of zsGreen + cells was significantly increased across all tumor APC subsets after administration of non-zsGreen-labeled necroptotic fibroblasts; this increase was particularly pronounced in the DC subsets examined (Fig. 5D) . Accordingly, the absolute number of zsGreen + cells among tumor DC subsets was increased after necroptotic cell exposure ( fig. S5D ). Because zsGreen expression was restricted to B16.F10-OVA tumor cells in this model, these results show that signals derived from necroptotic fibroblasts act in trans to increase either the rate of phagocytosis or the retention of tumor-associated antigen within tumor APC populations.
To further characterize the phenotype of tumor APCs in our model, we evaluated expression of the necrotic cell uptake marker CLEC9A on DCs and inhibitory PD-L1 on tumor cells and across different APC subsets. Exposure to necroptotic fibroblasts changed neither cell surface expression of either CLEC9A (Fig. 5E ) or PD-L1 (Fig. 5F ) nor the percentage of CLEC9A + ( fig. S5E ) or PD-L1 + ( fig. S5F ) populations from each cell subset. We also assessed the activation status of zsGreen + tumor APCs after exposure to dying fibroblasts within the TME. We first observed that zsGreen + tumor APCs expressed higher levels of the costimulatory marker CD80 on a per cell basis after administration of necroptotic fibroblasts; this increase was consistent across all six tumor APC subsets examined (Fig. 5G) . We also observed a significant increase in the geometric mean fluorescence intensity (gMFI) of CD80 after exposure to necroptotic cells when gating on zsGreen − (non-tumor antigenloaded) populations of each tumor APC subset ( fig. S5G ), revealing that stimuli derived from necroptotic fibroblasts increased CD80 expression across all tumor APCs, regardless of tumor antigen uptake status. This increase in activation marker expression correlated with an improved functional capacity of zsGreen + tumor APCs after exposure to necroptotic cells in the TME, as zsGreen + tumor APCs sorted ex vivo were capable of more robustly stimulating proliferation of previously activated transgenic OVA-specific (OT-I) CD8 + T cells in an in vitro coculture system (Fig. 5H ). This stimulatory effect was limited to CD8 + T cells with T cell receptor (TCR) specificity for tumor antigen, because ex vivo coculture of zsGreen + tumor APCs did not induce proliferation of T cells expressing an irrelevant lymphocytic choriomeningitis virus GP33 TCR (P14 transgenic TCR; fig. S5H ). Therefore, exposure to necroptotic cells in the TME increases not only the abundance but also the immunostimulatory quality of tumor antigen-loaded APCs.
Consistent with this, we found that necroptotic cells appear to enhance antigen uptake by phagocytes in a tumor-independent setting, because coculturing bone marrow-derived macrophages (BMDMs) with necroptotic B16.F10 tumor cells in vitro resulted in increased uptake of an inert dextran-fluorophore substrate included in the coculture, compared with BMDMs cultured with live B16.F10 cells (Fig. 5I, left panel) . Uptake of this bystander substrate was also associated with an increase in CD80 expression on both dextran + and zsGreen + BMDMs only after coculture with necroptotic B16. F10 cells (Fig. 5I , middle and right panels), whereas expression of the immunomodulatory markers CD206 and vascular cell adhesion molecule-1 (VCAM1) was decreased on zsGreen + BMDMs cocultured with necroptotic tumor cells compared with live tumor cell controls ( fig. S5I ). Collectively, these data indicate that stimuli derived from necroptotic cells increase antigen loading by phagocytic cell subsets and that this effect may constitute a conserved response to necroptotic cell-derived stimuli rather than a tissue-specific effect restricted to the TME.
Engineered AAVs can be used to specifically induce necroptosis of tumor cells in vitro
Intratumoral dying cell injection provides a cleanly controlled model for examining how exposure to stimuli derived from necroptotic cells can influence antitumor immune responses. However, an obvious caveat of this model is that it fails to assess immune responses to tumor cell necroptosis in situ. To address this, we sought to create reagents that would allow direct induction of necroptosis in tumors in vivo. To achieve this, we generated versions of RIPK3 fused to a constitutively oligomerizing ("co") domain, which consists of a high-affinity 2L6HC3-9 homotrimerizing domain that has been previously synthesized and described (35) . These chimeric forms of RIPK3 undergo oligomerization and activation upon their expression in cells, independent of any upstream signaling or the presence of a ligand. To deliver these reagents to tumor cells, we created AAVs containing genes encoding these constructs under control of a synthetic MND (myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted) promoter, enabling robust gene expression in target cells. Upon transduction of a target cell by these engineered AAVs, the chimeric pro-death protein of interest is expressed, constitutively oligomerizes, and leads to rapid and specific induction of RIPK3-dependent cell death (Fig. 6A and  fig. S6A ).
AAVs are a flexible tool for primary cell transduction, because several serotypes with varying cellular tropisms have been described. We therefore sought to identify an AAV serotype that would selectively deliver construct expression to B16.F10 melanoma cells. Using a hybrid AAV2.5 serotype (36), we observed robust transduction of . n = 3 technical replicates per group. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. All flow harvests performed 48 hours after dying cell injection. Error bars represent SEM. Data are representative plots from one to three independent experiments (E to I) or pooled from two to three independent experiments (A, B, and D).
cultured B16.F10 tumor cells within 24 hours of enhanced green fluorescent protein (eGFP)-AAV2.5 addition (Fig. 6B) . The AAV2.5 serotype also transduced nonleukocytic CD45 − cells within B16.F10-OVA tumors in vivo, exhibiting successful eGFP transduction in a higher percentage of CD45 − cells compared with AAV5, AAV6, AAV8, or AAV9 serotypes ( fig. S6B) . eGFP-AAV2.5 also had the lowest percentage of off-target transduction of CD45 + tumor-associated leukocytes in vivo ( fig. S6B ). We therefore concluded that the hybrid AAV2.5 serotype would maximize tumor cell transduction efficiency while limiting off-target transduction of immune cells when adapted for use in vivo, potentially limiting off-target toxicity effects.
Next, we characterized the kinetics of death induced by AAV2.5 particles that deliver genes encoding chimeric pro-death proteins in vitro. Transduction of B16.F10 tumor cells with necroptosis-targeting AAV2.5 (coRIPK3) or lytic necrosis-targeting AAV2.5 (coRIPK3C) led to 100% cell death within ~15 hours (Fig. 6C) . Consistent with induction of necroptosis by these reagents, we found that the pancaspase inhibitor zVAD-fmk did not affect death induction by coRIPK3 or coRIPK3C ( fig. S6C , left panel), whereas addition of the RIPK3 inhibitor GSK-843 eliminated coRIPK3C-induced death while decreasing coRIPK3-induced death; this latter effect was likely due to reverse signaling through the RIPK1/RIPK3 necrosome to induce apoptosis, as previously described ( fig. S6C , middle panel) (29, 30) . Consistent with this, incubation with both zVAD-fmk and GSK-843 eliminated all cell death associated with coRIPK3 treatment (fig. S6C, right panel) . This set of experiments shows that either necroptosis or lytic necrosis can be specifically and rapidly induced in B16.F10 tumor cells in vitro upon AAVmediated delivery of coRIPK3 or coRIPK3C, respectively.
Because our data using fibroblast injection pointed to activation of NF-B responses by RIPK3, but not by RIPK3C, as a key mediator of antitumor immune responses, we next assessed the ability of our AAV constructs to activate inflammatory transcription in dying cells. To do this, we infected B16.F10 tumor cells in vitro with AAVs encoding coRIPK3 or coRIPK3C for 10 hours (a time point at which tumor cells have not yet undergone membrane permeabilization, allowing for nucleic acid isolation) and then harvested total RNA for NanoString analysis. Transduction of tumor cells with coRIPK3 yielded a distinct transcriptional signature compared with cells transduced with coRIPK3C ( fig. S6D ). Further examination of this signature revealed that necroptotic B16.F10 cells exhibited up-regulated expression of numerous NF-B-dependent gene targets, including Lta, Ltb, Cd40, Cd86, Mef2a, Nod2, and Nos2 in comparison with lytic necrotic tumor cells (Fig. 6D) . In addition, necroptotic B16. F10 cells also up-regulated expression of several inflammatory chemokines and cytokines, including Cxcl1, Cxcl3, Ccl2, Ccl3, Ccl4, Ccl21a, Ccl22, Il12b, Il22, and Ifng (Fig. 6D) . Up-regulated transcript levels for several of these target genes were independently validated via quantitative reverse transcriptase PCR (qRT-PCR) ( fig. S6E ). Together, these data indicate that the induction of tumor cell death via coRIPK3 transduction in vitro leads to an inflammatory transcriptional signature consistent with immunogenic necroptosis (20) . Furthermore, this gene signature depends on the assembly of the RIPK1/RIPK3 necrosome via RHIM-RHIM interactions, because it is absent in tumor cells transduced with coRIPK3C.
Administration of necroptosis-targeting AAVs in conjunction with -PD-1 in vivo promotes durable tumor clearance
After validation of our PCD-targeting AAVs in vitro, we applied these tools to study antitumor responses in vivo. Intratumoral administration of coRIPK3 conferred control of B16.F10-OVA tumor outgrowth (Fig. 7A) and extension of animal survival ( fig. S7A ) in comparison with intratumoral injection of coRIPK3C or control eGFP. Analysis of tumor homogenates revealed increased concentrations of numerous beneficial antitumor cytokines and chemokines after coRIPK3 administration, including IFN-, CCL3, CCL5, and CXCL10 (Fig. 7B) , whereas levels of IL-6, CXCL1, and CXCL2 were unchanged ( fig. S7B ). Furthermore, we observed abscopal tumor control effects in a bilateral B16.F10-OVA flank tumor model, as coRIPK3 administration conferred control over tumor outgrowth in both treated (ipsilateral) and untreated (contralateral) tumors (Fig. 7C ) and significantly extended animal survival ( fig. S7C ). These results recapitulate the tumor control effects that we observed in a bilateral tumor model using necroptotic fibroblast administration, showing that enforced RIPK3 activation via AAVs can similarly promote tumor control that is associated with increased intratumoral levels of inflammatory chemokines and cytokines. Next, we tested whether necroptosis-targeting AAVs could similarly protect mice from single B16.F10-OVA tumor outgrowth upon coadministration with -PD-1. Not only did administration of coRIPK3 with isotype controls significantly extend animal survival (Fig. 7D ) and inhibit tumor growth ( fig. S7D ) in comparison with eGFP-treated control mice, but also, the coadministration of coRIPK3 with -PD-1 led to robust responses, with improved overall survival (Fig. 7E) , complete tumor clearance in 69.2% of mice ( fig. S7E , right panel), and significant control over tumor outgrowth ( fig. S7E, left  panel) . Again, these tumor elimination responses closely paralleled those observed in the intratumoral necroptotic fibroblast injection model.
B16.F10-OVA tumor control after coadministration of coRIPK3 and isotype or -PD-1 required the presence of CD8 + leukocytes, because depletion of CD8 + cell subsets via antibody injection completely abrogated the protective effects of coRIPK3 and immunoglobulin G2a (IgG2a) or -PD-1 (Fig. 7F and fig. S7F ). In addition, mice lacking BATF3 + cDC1 also failed to control B16.F10-OVA tumors after coRIPK3 and -PD-1 treatment regimen (Fig. 7G and fig. S7G ). Considering that tumor control by necroptotic fibroblasts also necessitated the presence of these immune cell compartments, these experiments revealed similar effector cell subset requirements between both intratumoral dying fibroblast and intratumoral AAV models. With these requirements in mind, we next sought to test whether the mice that had successfully cleared their B16.F10-OVA tumors after dual therapy (Fig. 7E) had developed protective immune memory. To this end, we rechallenged surviving animals with identical tumor cells on the same flank that initially bore the B16.F10-OVA tumors (Fig. 7H, left  panel) . Most of these animals were protected from mortality due to tumor outgrowth (Fig. 7H, right panel) , whereas only 12.5% of mice regrew tumors ( fig. S7H ) compared with 100% of naïve controls.
Overall, these data demonstrate that intratumoral administration of necroptosis-targeting AAVs in conjunction with -PD-1 confers durable, immune-mediated tumor rejection similar to that observed upon administration of intratumoral necroptotic NIH 3T3 fibroblasts.
AAV-mediated transduction of tumor cells allows for enforced expression of activated RIPK3, regardless of the expression status of endogenous RIPK3. Considering the beneficial effects of enforced RIPK3 activation that we observed in our murine melanoma model, we asked how endogenous levels of RIPK3 correlated with survival outcomes in human cancer patients. Using tumor biopsy RNA sequencing data available through The Cancer Genome Atlas (TCGA) database, we stratified human skin cutaneous melanoma patients based on upper (high) and lower quartiles (low) of RIPK3 transcript expression within the tumor tissue. Patients with high tumor RIPK3 expression exhibited significantly improved survival outcomes compared with low RIPK3-expressing patients (Fig. 7I) . Furthermore, multivariate Cox regression modeling revealed a negative coefficient (−0.175), indicating that high expression of RIPK3 is correlated with a better survival outcome (Fig. 7I) (37) . Together, these results show that higher levels of RIPK3 expression within melanoma tumors are associated with improved survival in a subset of human patients.
DISCUSSION
Distinct forms of PCD can differentially instruct subsequent immune responses mounted against antigens derived from dying cells. Here, we describe a role for RIPK1/RIPK3 activation in which necroptotic fibroblasts within the TME drive increased antigen uptake and activation of tumor APCs to potentiate tumor-specific CD8 + T cell immunity, which synergizes with -PD-1 coadministration to confer durable tumor rejection (Fig. 8) . These gross tumor control effects are recapitulated in a model of AAV-mediated induction of necroptosis within melanoma tumor cells in situ, indicating that enforced activation of RIPK3 may lead to beneficial inflammatory signaling that is conserved across multiple cell types. Our data indicate that tumor control by necroptotic cells is primarily mediated via the activation of a RIPK1/RIPK3/NF-B signaling axis independently of cell lysis, because MLKL deficiency in fibroblasts does not abrogate tumor control (Fig. 3F) , whereas NF-B inhibition (Fig. 3E ) or use of a mutant form of RIPK3 that triggers cell lysis without engaging RIPK1-dependent transcription (Fig. 3C) eliminates the therapeutic efficacy of these cells. Thus, although we are engaging necroptotic cell death (as defined by activation of MLKL by RIPK3) in most experiments reported here, activation of transcription that parallels cell death is likely the cause of the beneficial immune stimulation we observe. These findings join a growing number of reports of biological effects of RIPK1/RIPK3 signaling that are independent of MLKL activation (21, (38) (39) (40) (41) .
Existing therapies to target RIPK1/RIPK3 activation in vivo exhibit variable efficacy due to off-target effects of global caspase inhibition (42) and the differential expression status of endogenous RIPK3 in tumor cells (23, 24) . AAV-mediated reconstitution of constitutively active RIPK3 within tumor cells represents a previously unidentified strategy to specifically induce this pathway independently of any endogenous signaling requirements. Another group recently reported that intratumoral delivery of mRNA-encoding MLKL to promote cell lysis in situ conferred protection in murine melanoma and colon carcinoma models (43) , and although our findings diverge from theirs with regard to a requirement for NF-kB signaling within dying cells, both studies support the idea that reconstituting expression of necroptotic signaling components can promote antitumor immunity. Considering that high levels of RIPK3 expression in human melanoma tumors correlate with improved patient survival (Fig. 7I) , we propose that such strategies to restore or increase necroptotic signaling in human tumors represent a promising therapeutic target in future translational research.
Future work will need to define the specific signals derived from necroptotic cells that are responsible for mediating our observed antitumor immune responses. Across both dying cell and AAV administration models, the therapeutic effects of necroptotic cells appear to occur independently of MLKL activation, cell lysis, and subsequent DAMP release, suggesting that NF-B transcriptional signaling downstream of the RIPK1/RIPK3 necrosome complex is required for therapeutic efficacy of necroptosis in the TME. Our observation of increased tumor-derived antigen within tumor APCs exposed to necroptotic cells is consistent with a previous report of necrotic debris being ingested alongside extracellular contents via macropinocytosis (44) . However, the specific signals derived from necroptotic cells that are responsible for driving macropinocytosis to increase sampling of the local extracellular microenvironment remain unknown; our data imply that these signals are defined by cytokines, rather than DAMPs, produced by dying cells. Defining the mechanistic targets of RIPK1/RIPK3 activation and how these targets interact with tumor APCs to drive either increased macropinocytosis or improved retention of tumor antigen to better stimulate cytotoxic CD8 + T cells remains an important area for future study.
The overarching goal of tumor immunotherapy is to engage cytotoxic CD8 + T cells to kill tumor cells. This branch of the immune response evolved to combat intracellular pathogens such as viruses; treatments that activate innate immune pathways associated with viral sensing within tumors have therefore proven effective at provoking cytotoxic antitumor immunity. Such approaches include agonism of nucleic acid sensing via cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) (45, 46) and TLR pathways (47) . The necroptotic pathway likely evolved to combat viral infection via elimination of the replicative niche and also promotes cross-priming of the CD8 + T cell responses required for viral elimination (20) . Activation of this pathway within tumors can therefore be considered an additional strategy to direct antiviral immunity toward tumor elimination. Although much work remains to validate these findings in clinically relevant models, our data suggest that RIPK1/RIPK3 activation within the TME warrants further development as a component of tumor immunotherapy.
MATERIALS AND METHODS
Study design
Pilot studies were used to estimate mean differences in tumor growth between treatment groups. Using the Sample Size Calculator resource (Boston University), we calculated biological replicate numbers needed to avoid experimental underpowering by using the percent difference in group means from pilot studies, with a power level of 0.80 and  level = 0.05. Age-matched mice were randomly assigned to treatment groups, and tumor measurements were conducted by a researcher blinded to treatment groups for at least one experimental replicate.
Cell culture B16.F10-OVA, LL/2-OVA, NIH 3T3, and human embryonic kidney (HEK) 293T cells were maintained in Dulbecco's modification of Eagle medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 2 mM l-glutamine, 10 mM Hepes, and 1 mM sodium pyruvate (complete DMEM). E.G7-OVA cells were maintained in RPMI 1640 supplemented with 10% FBS, 2 mM l-glutamine, 10 mM Hepes, 1 mM sodium pyruvate, 0.05 mM -mercapthoethanol, geneticin (0.4 mg/ml; G418), and d-glucose (4.5 g/liter). B16.F10 and LL/2 cell lines were transduced with a plasmid (pSLIK) encoding activatable versions of caspase-9 or RIPK3 under thyroid response element control; thus, these cells were cultured in doxycycline (1 g/ml; Sigma-Aldrich) for 18 hours to induce construct expression before harvesting as described below for dying cell injections. BMDMs were cultured in complete DMEM, penicillin/streptomycin, and recombinant macrophage colonystimulating factor (20 ng/ml), and differentiated for 7 days before plating for experiments. All cells were cultured at 37°C with 5% CO 2 .
Mice C57BL6/J (B6/J) mice were purchased (the Jackson Laboratory) and allowed to acclimate up to 1 week before experiment initiation. All other genotypes were bred and housed under specific pathogen-free conditions at the University of Washington. All animals were maintained according to protocols approved by the University of Washington Institutional Animal Care and Use Committee.
Tumor models
Six-to 10-week-old female (B16.F10-OVA, E.G7-OVA) or male (LL/2-OVA) mice were injected subcutaneously on the right flank with 1 × 10 5 (B16.F10-OVA, E.G7-OVA) or 2 × 10 5 (LL/2-OVA) tumor cells, mixed in a 1:1 volumetric ratio with the basement membrane matrix Matrigel High Concentration (Corning) for a final injection volume of 100 l. For bilateral tumor experiments, mice were equivalently implanted with tumor cells on the left flank on the same day of right flank tumor injection. As previously described (45) , tumor volume was calculated using the following formula: volume = short axis 2 × long axis × 0.523. Mice were euthanized once tumor burden reached a volume of ≥2000 mm 3 . Mice that developed skin ulceration over the tumor site were excluded from experimental analyses. Complete tumor clearance was determined by the absence of a palpable tumor mass at the site of tumor injection.
Intratumoral dying cell injections NIH 3T3, B16.F10, or LL/2 cells stably transduced with pro-death constructs were harvested and activated as previously described (20) . Briefly, 5 × 10 6 cells/ml were incubated in complete DMEM and 1 mM B/B homodimerizer (Clontech) for 15 min at 37°C. Cells were then washed with cold phosphate-buffered saline (PBS), resuspended at 20 × 10 6 cells/ml, and kept on ice before injection. Dying cells (1 × 10 6 ) were administered intratumorally in 50 l. Remaining cells were replated and cultured at 37°C overnight to ensure that >95% of treated cells underwent PCD. Dying cells were administered on days 6, 8, and 10 after initial tumor challenge. For experiments involving IB inhibition, NIH 3T3 cells were pretreated with 10 M BAY-117085 (Cayman Chemical) for 45 min before harvesting for B/B homodimerizer incubation, as described (20) .
In vivo antibody administration
A total of 200 g of -CD8 (clone 2.43, Bio X Cell), -CD4 (clone GK1.5, Bio X Cell), -PD-1 (clone RMP1-14, Bio X Cell), or respective isotype controls were administered to mice via intraperitoneal injection on days 5, 7, 9, and 11 after initial tumor challenge. NK cell depletion experiments followed the same dosing protocol, using 250 g of -NK1.1 (clone PK136, Bio X Cell). CLEC9A blocking experiments followed the same dosing protocol, using 400 g of -CLEC9A (clone 7H11, Bio X Cell) or isotype control, as described (27) .
Recombinant AAV cloning
Design and sequencing analysis of all plasmids was performed using Geneious software v.7.1 (48) . The 2L6HC3-13 trimer homooligomer domain was a gift from D. Baker (35) . Trimerizing RIPK3 constructs were directly cloned into a single-stranded AAV vector using multifragment assembly (In-fusion HD, Takara Biosciences). AAV backbone was linearized using SnaBI digest as previously described (49) . Primers for amplification of gene fragments were designed to contain 20-base pair 5′ and 3′ homology to neighboring fusion sequences, and PCR amplification was carried out using Q5 polymerase (New England Biosciences). The shortened 3′ untranslated region woodchuck hepatitis virus posttranscriptional regulatory element (UTR WPRE) and polyA elements were amplified from pAAV-CW3SL-EGFP, a gift from B.-K. Kaang (Addgene no. 61463). Sense (S) and antisense (AS) primer sequences were as follows: fragment 1 (MND promoter), (S) CCGCCATGCTACTTATCTACGGAGTCGTGACCTAG-GGAACAGAGAAACAGG and (AS) TTCGAGGAAGTCAAAACAGC-GTGG; fragment 2 (RIPK3 and RIPK3C), (S) CGCTGTTTTGACTTCCTC-GAACCATGTCTTCTGTCAAGTTATGG, (full-length RIPK3 AS) AGAACCACTCCCTTCTGATCCTTCGGAACCCGTACGCTTGT-GGAAGGGCTGCCAGC, and (RIPK3C AS) AGAACCACTCCCTTCT-GATCCTTCGGAACCCGTACGTCATTGGATTCGGTGGGGTC; fragment 3 (2L6HC3-13 homotrimer domain), (S) GATCAGAAG-GGAGTGGTTCTCATATGGGTACGAAATACG and (AS) CAGAG-GTTGATTATGCGGCCTTAGTCACTTTTGGCGTTAATTTTC; and fragment 4 (sWPRE/polyA), (S) GGCCGCATAATCAACCTCTGG and (AS) CCGCCATGCTACTTATCTACAAAAAACCTCCCA-CATCTCCCCC.
The MND-eGFP self-complementary AAV was a gift from D. Rawlings. The DNA sequence of inserted elements was verified by sequencing, and the integrity of the viral inverted terminal repeat (ITR) within the pAAV backbone was confirmed by restriction digest using AhdI, BglI, or SmaI, before viral production.
AAV production, purification, and quantification AAVs were produced as described (50, 51) . Briefly, AAV stocks were generated in HEK293T cells via polyethylenimine transfection using a vector and a serotype helper (pLTAAV). Cells were harvested 48 hours after transfection, lysed via freeze-thaw cycling, treated with Universal Nuclease (100 U/ml; Thermo Fisher) at 37°C for 30 min, and purified via centrifugation over an iodixanol density-step gradient. Titers of viral stocks were determined via qRT-PCR analysis in conjunction with TaqMan reagents and a ViiA 7 Real-Time PCR apparatus (Applied Biosystems). qRT-PCR for viral titer used primers targeting the conserved ITR, using the following sequences: (forward) GGAAC-CCCTAGTGATGGAGTT and (reverse) CGGCCTCAGTGAGCGA.
Intratumoral AAV injections
Infectious units (IFU; 1 × 10 11 ) of respective AAVs were administered intratumorally in 50 l. Virus aliquots used for in vivo experiments were thawed once after initial freezing after purification. AAV injections were administered on days 6, 8, and 10 after initial tumor challenge.
Flow cytometry and cell sorting
Leukocytes were isolated from either the tumor-adjacent inguinal lymph node or spleen by mashing over a 70 M strainer or from tumor tissue by digesting minced tumors in 1× PBS, collagenase A (2.6 mg/ml; Sigma), and deoxyribonuclease I (23 U/ml; Sigma) at 37°C with agitation for 45 min before mashing tissue over a 70 M strainer. Cells (1 × 10 6 to 3 × 10 6 ) were blocked with anti-CD16/32 (BD Biosciences) and stained with Zombie viability dye (BioLegend) at room temperature for 30 min. Cells were then incubated with appropriate fluorochrome-conjugated antibodies in 1× PBS, 0.5% FBS, and 2 mM EDTA at 4°C for 1 hour. Permeabilization and intranuclear staining were performed using a Foxp3 Intranuclear Transcription Factor Staining Kit (eBioscience). Data were collected using an LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software (TreeStar). For sorting of zsGreen + tumor APC populations, B16.F10-OVA-zsGreen tumors were harvested 48 hours after intratumoral dying cell injection, leukocytes were processed and stained as described above, and subsets were sorted using a FACSAria II (BD Biosciences).
OT-I/P14 proliferation assay
Lymph nodes and spleens from OT-I or P14 TCR transgenic mice were processed and enriched for CD8 + T cells via negative selection using biotinylated antibodies against B220, CD4, CD11b, CD11c, and Ter119 (eBioscience) followed by magnetic separation. Purified transgenic T cells were activated via 6-day coculture with irradiated splenocytes pulsed with SL8 (100 ng/ml; for OT-I) or GP33 (for P14) peptides (InvivoGen). A total of 20,000 previously activated transgenic T cells were labeled with 5 M CellTrace Violet (Thermo Fisher) and plated with 4000 sorted zsGreen + tumor APC subsets in 96-well U-bottom plates for 72 hours before analysis of proliferation dye dilution via flow cytometry.
Murine cytokine assessment
To evaluate serum cytokine levels, sera were harvested from mice receiving indicated intratumoral treatments 48 hours after dying cell administration and stored for <2 weeks at −80°C. As a positive control for systemic inflammation, B6/J mice were injected intraperitoneally with the STING agonist DMXAA (40 mg/kg; ApexBio), and sera were harvested 5 hours after injection and then frozen at −80°C. To evaluate intratumoral cytokine levels, tumors were harvested 48 hours after dying cell administration or 72 hours after AAV administration. Tumors were then minced and homogenized using metal beads with vigorous shaking in tubes and then frozen at −80°C. To evaluate cytokine levels in vitro, 3 × 10 5 B16.F10 cells were infected with 1 × 10 11 IFU of AAV for 18 hours, and supernatants were frozen at −80°C. Thawed samples were analyzed using a T helper cell 1 (T H 1)/T H 2 ProcartaPlex Panel 1 Luminex kit (Thermo Fisher).
NanoString RNA analysis and qRT-PCR B16.F10 cells (2 × 10 6 ) were infected with 1 × 10 11 IFU of respective AAVs for 10 hours. Total RNA was isolated using a NucleoSpin RNA Kit (Macherey-Nagel) and run on an nCounter Sprint in conjunction with an nCounter Mouse Inflammation V2 Panel (NanoString). Data were normalized and analyzed using nSolver software (NanoString). For target gene validation, oligo(dT) random hexamers and SuperScript III RT (Life Technologies) were used to synthesize cDNA from the same total RNA samples used for NanoString analysis. Fluorogenic qRT-PCR analysis was performed using previously published oligonucleotide primer sequences using SYBR green reagents and a ViiA 7 Real-Time PCR apparatus (Applied Biosystems). Cycle threshold (CT) values for target genes were normalized to CT values of the housekeeping gene Gapdh (CT = CT Target -CT Gapdh ) and subsequently normalized to baseline control values (CT = CT Experimental -CT Control ).
In vitro cell death assay B16.F10-OVA cells (1 × 10 5 ) were infected with 1 × 10 11 IFU of respective AAVs in 24-well plates for 24 hours. Cell viability was evaluated via incorporation of cell viability dye Sytox Green (Molecular Probes) or Yoyo-3 (200 nM; Life Technologies) and quantified using a two-color IncuCyte Zoom bioimaging platform (Essen Biosciences), as described (52) . Where indicated, 50 M zVAD-fmk (SM Biochemicals) or 100 nM GSK-873 (GlaxoSmithKline) were added to inhibit pancaspase activation or RIPK3 activation, respectively.
CRISPR-Cas9 gene targeting
The following guide RNA (gRNA) sequences were cloned into a pRRL-Cas9-T2A-puromycin CRISPR-Cas9 lentiviral vector [a gift from D. Stetson (53)]: 5′-GCGAGGTATTCGGCTCCGCG-3′ (murine nontargeting gRNA) (54) and 5′-GCACACGGTTTCCTAGAC-GC-3′ (murine Mlkl gRNA). Constructs were transduced into NIH 3T3 and acRIPK3 cells using standard lentiviral transduction protocols and selected in puromycin (1 g/ml).
siRNA knockdown MLKL −/− NIH 3T3 cells (2 × 10 5 ) +acRIPK3 were transfected with siGenome SMARTpool small interfering RNA (siRNAs) (Dharmacon) targeting murine RIPK1 (M-040150-01), murine caspase-8 (M-043044-01), murine cFLIP (M-041091-01), or nontargeted "scramble" pool (D-001206-14), using lipofectamine siRNA Max (Life Technologies). Forty-eight hours after transfection, cells were replated and treated with 100 nM B/B homodimerizer (Clontech), and cell death kinetics were characterized as described above.
Western blot
Cell lysates were harvested and quantitated using a BCA Protein Assay (Thermo Fisher). Thirty milligrams of total protein per sample were separated using SDS-polyacrylamide gel electrophoresis gels (Invitrogen) and detected using traditional protocols. The following antibodies were used for protein detection: rat -MLKL clone 3H1 (EMD Millipore), rabbit -FKBP12 (Thermo Fisher), mouse -actin C4 (EMD Millipore), goat -rat IgG-horseradish peroxidase (HRP) (Santa Cruz Biotechnology), donkey -rabbit IgG-HRP (Santa Cruz Biotechnology), and goat -mouse IgG-HRP (Santa Cruz Biotechnology).
In vitro dextran uptake assay
BMDMs were plated in a 1:5 ratio with either live or acRIPK3-expressing B16.F10-zsGreen tumor cells. acRIPK3 cells were induced to die upon 18 hours incubation with doxycycline (1 g/ml) before coculture with BMDMs and then incubated with 100 nM B/B homodimerizer (Clontech) for 24 hours before adding dextranphycoerythrin (PE)-TexasRed (1 mg/ml; 10,000 molecular weight, Thermo Scientific). Dextran incubations were performed in triplicate at either 4° or 37°C for 30 min, and plates were tapped every 10 min to mix. Cells were washed three times, stained with fluorochromeconjugated antibodies, and immediately analyzed on a flow cytometer. Dextran uptake was calculated as follows (31) : gMFI = (gMFI dextran binding at 37°C − gMFI dextran binding at 4°C).
TCGA analysis
The OncoLnc package (37) was used to analyze RNASeqV2 and overall survival data generated by TCGA Research Network database (55) . OncoLnc was used to conduct survival analyses using multivariate Cox regression modeling, assign log-rank P values and Cox coefficients to assess significance and generate Kaplan-Meier survival curves.
Statistics
Unless otherwise noted in figure legend, data represent means ± SEM. Survival curves were analyzed via Mantel-Cox log-rank test unless noted otherwise. All other experiments were compared using parametric two-tailed student's t test, chi-square test, or one-way or two-way analysis of variance, with appropriate corrections for repeated measures of tumor growth curves. All statistical analyses were performed using GraphPad Prism software unless noted otherwise.
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